Introduction {#s1}
============

HCV infections are on the rise in the United States, reflecting increasing rates of opioid addiction ([@bib33]). An HCV vaccine is urgently needed to control the epidemic, but vaccine development is challenging due to the enormous genetic diversity of the HCV envelope proteins ([@bib32]). The HCV genome encodes two structural proteins, E1 and E2, that associate to form a noncovalent heterodimer, E1E2 ([@bib11]). Potent bNAbs isolated from HCV-infected individuals predominantly target conserved epitopes in the front layer of the E2 glycoprotein. The majority of bNAbs that bind to the front layer are derived from *VH1-69* genes ([@bib28]), which are also associated with bNAbs that target conserved epitopes on influenza virus and HIV-1 envelope glycoproteins ([@bib5]).

We recently described crystal structures of two *VH1-69* bNAbs, HEPC3 and HEPC74, isolated from individuals who spontaneously cleared HCV infection ([@bib10]). Both bNAbs utilized a disulfide motif in their CDRH3 regions to recognize a conserved epitope in the front layer of E2. While the HEPC3 and HEPC74 CDRH3 loops adopted a straight ß-hairpin conformation, the *VH1-69*-encoded AR3A and AR3C bNAbs that were isolated from an individual with a chronic HCV infection included bent CDRH3 loops that contained an analogous disulfide motif ([@bib17]). Since the two bNAbs with straight CDRH3s were isolated from individuals who spontaneously cleared HCV infection and the two bNAbs with bent CDRH3s were isolated from a single chronically-infected individual, we wondered if some individuals are naturally predisposed to make antibodies with straight or bent CDRH3s and/or whether the straight CDRH3 conformation was related to the ability to clear HCV infection. Among bNAbs isolated from a chronically-infected individual ([@bib20]), we found AR3X, a *VH1-69*-encoded antibody that included a CDRH3 with a disulfide motif and an unusually long 14-amino acid-long insertion in CDRH2 ([Figure 1A](#fig1){ref-type="fig"}). AR3X provided an opportunity to explore the structural plasticity of *VH1-69*-derived anti-HCV bNAbs with a disulfide-containing CDRH3 and to determine the impact of a long CDRH2 insertion on the recognition of the conserved epitope in E2 front layer.

![AR3X includes a 14-residue insertion in CDRH2.\
(**a**) Sequence alignment of a portion of the heavy chain variable region gene sequences of AR3X and the AR3X germline precursor (AR3Xrua) (uppercase letters) and the *VH1-69* gene segment (lowercase letters). The CDRH2 insertion is indicated by a dark gray box with the position of the potential duplication site indicated by a light gray box. CDR loops were defined based on Kabat nomenclature [@bib13]). Dots indicate identical nucleotides and dashes indicate gaps. (**b**) Sequence alignment of the CDRH2 insertion and the potential duplication origin site in *VH1-69.* (**c**) Amino acid sequence alignment of the AR3X CDRH3 and the AR3X germline precursor genes determined by IMGT/V-QUEST. Dots indicate identical amino acids and dashes indicate regions encoded by other gene segments or N-nucleotide additions. Two cysteines encoded by the D gene segment are highlighted in bold and underscored. (**d**) Amino acid sequence alignment of the heavy chain variable region sequences of AR3X, AR3X ΔINS (AR3X without insertion), AR3Xrua (germline precursor of AR3X), and AR3Xrua + INS (germline precursor of AR3X with insertion). CDR loops were defined based on Kabat nomenclature and colored purple (CDRH1), orange (CDRH2), and blue (CDRH3), with the CDRH2 insertion highlighted in bold. Dots indicate identical amino acids and dashes indicate gaps. (**e**) Alignment of AR3X, AR3A, AR3C, HEPC3, and HEPC74 CDRH3 sequences. The AR3X sequence is highlighted in red and the two cysteines in each CDRH3 are underscored.](elife-53169-fig1){#fig1}

Results {#s2}
=======

The most likely scenario resulting in the insertion into the CDRH2 of AR3X involves a duplication event, as the CDRH2 insertion has 69% identity with the N-terminal sequence preceding the CDRH2 ([Figure 1B](#fig1){ref-type="fig"}). Similar to other front layer-specific bNAbs with the CDRH3 disulfide motif ([Figure 1E](#fig1){ref-type="fig"}), the cysteines in the AR3X CDRH3 region are encoded by the human D gene segment 15 (IGHD2-15) ([Figure 1C](#fig1){ref-type="fig"}). The C-terminal portion of the AR3X CDRH3 is likely encoded by human J-gene segment 3\*02 (J3\*02). Not including the 14-amino acid insertion in CDRH2, AR3X shares 91% nucleotide identity with the *V~H~1-69* gene segment and includes 17 somatic mutations ([Figure 1D](#fig1){ref-type="fig"}). To investigate the importance of the CDRH2 insertion and the effects of somatic mutations on AR3X binding and neutralization, we generated a panel of AR3X variants: AR3X ΔINS (AR3X without the CDRH2 insertion), AR3Xrua (germline precursor of AR3X, which lacks the CDRH2 insertion and somatic mutations), and AR3Xrua + INS (germline precursor of AR3X with the CDRH2 insertion) ([Figure 1D](#fig1){ref-type="fig"}).

We evaluated the binding of AR3X and AR3X variants to a panel of E2 ectodomain (E2ecto) proteins representing the E2 envelopes from 19 HCV genotype 1 strains. We also tested the binding of AR3X and AR3X variants to E2ecto proteins from genotypes 2, 3, 4, 5, and 6 strains. AR3X recognized all 19 E2 envelopes from genotype 1 including the 1a116 strain, which was not recognized by other front layer-specific bNAbs that include the CDRH3 disulfide motif ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [@bib10]). AR3X also recognized E2 envelopes from genotypes 2, 3, 4, 5, and 6 ([Figure 2A](#fig2){ref-type="fig"}). In contrast to mature AR3X, the AR3X ΔINS protein that lacks the CDRH2 insertion bound only 4 of the 25 variants, indicating that the CDRH2 insertion mediates the breath of binding. While AR3Xrua failed to bind any E2ecto proteins, AR3Xrua + INS recognized 1 of the 25 variants, further highlighting the importance of the CDRH2 insertion in initial recognition of the E2 antigen by naïve B cells. The fact that AR3Xrua + INS only bound to one HCV strain, whereas mature AR3X recognized all strains, indicated that somatic mutations, in addition to the CDRH2 insertion, are required for breath of binding and optimal E2 recognition. Consistent with our previous studies in which the strain 1a157 E2ecto envelope was recognized by HEPC3, HEPC74, AR3C and their germline precursors ([@bib10]), AR3X and two AR3X variants (AR3X ΔINS, AR3Xrua + INS) also bound to 1a157, suggesting that immunogens based on the genotype 1 1a157 ectodomain sequence could be used to stimulate the development of potent front layer-specific bNAbs ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![The CDRH2 insertion in AR3X is required for maximal binding and broad neutralization.\
(**a**) Heat map showing the binding of AR3X and its variants to a panel of HCV E2ecto proteins. The EC~50~ value for each E2ecto-mAb combination is shown, with dark red, orange, yellow, or white shading indicating high, intermediate, low, or no detectable binding, respectively. The \> symbol indicates EC~50~s greater than 10 µg/mL or EC~50~s in which the OD~450~ values at the highest antibody concentration tested were lower than 0.5. One experiment representative of two independent experiments is shown. (**b**) Heat map showing neutralization activities of AR3X and AR3X variants measured using a panel of genotype 1 HCVpp. IC~50~ values for each virus-mAb combination are shown. The \> symbol indicates IC~50~s greater than 100 µg/mL or IC~50~s in which the percent neutralization at the highest antibody concentration tested was lower than 50%.](elife-53169-fig2){#fig2}

To evaluate the neutralization breadth of AR3X variants, we evaluated antibodies in an in vitro neutralization assay using a panel of 19 genotype 1 HCV pseudoparticles (HCVpp) that represents 94% of the amino acid polymorphisms present at \>5% frequency in a reference panel of 643 genotype 1 HCV isolates from GenBank ([@bib22]). Only mature AR3X exhibited neutralization activity, neutralizing 17 of 19 HCV strains ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The neutralization breadth of AR3X (89%) was slightly lower than the breath of AR3C bNAb (100%) ([@bib10]), which was isolated from the same HCV-infected individual ([@bib20]). AR3X variants failed to neutralize HCV isolates, suggesting that both the CDRH2 insertion and somatic mutations are required for the broad neutralization activity of AR3X.

We and others described two classes of *VH1-69* bNAbs with a CDRH3 disulfide motif: bNAbs with a straight CDRH3 (HEPC3 and HEPC74) and bNAbs with a kinked CDRH3 (AR3A and AR3C) ([@bib10]; [@bib17]; [@bib28]; [Figure 3](#fig3){ref-type="fig"}). To determine to which class AR3X belongs, we determined the crystal structure of AR3X in complex with E2ecto from the 1b09 HCV strain ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The 2.2 Å AR3X-E2ecto structure demonstrated that, similar to previously-characterized HCV bNAbs that recognize the neutralizing face of E2 ([@bib10]; [@bib17]; [@bib28]), AR3X binds to the conserved epitope in the E2 front layer ([Figure 4A](#fig4){ref-type="fig"}). The AR3X CDRH3 loop contains two cysteines that form a disulfide bond, as seen in multiple other E2 front layer-binding bNAbs, and the AR3X CDRH3 adopts the straight conformation we previously described in the HEPC3 and HEPC74 bNAbs that were isolated from an individual who cleared HCV infection ([@bib10]; [Figure 3](#fig3){ref-type="fig"}). By contrast, the CDRH3s of AR3A and AR3C, which were isolated from the same HCV-infected individual as AR3X ([@bib20]), are bent ([@bib17]; [@bib28]). The tip of the AR3X CDRH3 loop interacts with the same conserved residues in the front layer of E2 as the CDRH3 tips in the other HCV bNAbs ([Figure 4e](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

![The shared CDRH3 motif in E2 front layer-specific HCV bNAbs adopts different orientations.\
Fab structures in liganded state of AR3A (PDB 6BKB), AR3C (PDB 4MWF), AR3X (this paper), HEPC3 (PDB 6MEI), and HEPC74 (PDB 6MEH). The structures were superimposed on their V~H~ domains. Protein backbones are shown as ribbons and CDR loops are purple (CDRH1), orange (CDRH2), and blue (CDRH3).](elife-53169-fig3){#fig3}

![Details of the AR3X interactions with E2ecto.\
(**a**) Crystal structure of the AR3X-E2ecto complex. E2ecto is shown as a cartoon representation within a transparent surface with N-glycans highlighted as sticks and disulfide bonds shown as yellow sticks. The AR3X Fab is shown in a surface representation with highlighted CDRs. (**b**) Comparison of buried surface areas (BSAs) of E2ecto on the HC and LC of AR3X. (**c**) Percentage of BSA contributed from CDRH loops of the total BSA on the AR3X HC. The portion of CDRH2 within the CDRH2 insertion is separated from the main pie chart. (**d**) Length distribution of human CDRH2s. Human CDRH2 lengths were extracted from the online abYsis system (<http://www.bioinf.org.uk/abysis/>) using the Kabat numbering scheme [@bib13]). (**e**) Interactions of AR3X heavy chain CDRs with E2ecto. CDRs are purple (CDRH1), orange (CDRH2), and blue (CDRH3) tubes. Disulfide bonds are shown as yellow sticks. (**f**) CDRH2 interactions with E2ecto. Interacting residues are shown as sticks. AR3X CDRH1 -- purple, AR3X CDRH2 -- orange, and AR3X CDRH3 -- blue. Disulfide bonds are shown as yellow sticks. Potential H-bonds are shown as black dashed lines, and residues at the interface are indicated. (**g**) CDRH3 interactions with E2ecto. Interacting residues shown as sticks. For clarity, only the CDRH3 of AR3X is shown. Disulfide bonds are shown as yellow sticks and E2 glycans are shown as sticks with light blue, red, and dark blue colors for carbon, oxygen, and nitrogen atoms, respectively. Potential H-bonds and salt bridges are shown as black or red dashed lines, respectively. Residues at the interface are indicated.](elife-53169-fig4){#fig4}

Overall, AR3X has a similar binding footprint to the footprints of HEPC3, HEPC74, AR3C, and AR3A, sharing multiple contact residues in the front layer and CD81 receptor-binding loop ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). As also found for these other front layer-specific bNAbs, AR3X's contacts with E2ecto almost exclusively involved V~H~ domain residues, burying 1,250 Å^2^ (98% of the total Fab buried surface area; BSA) ([Figure 4B](#fig4){ref-type="fig"}), with the CDRH3 accounting for 44.5% (556 Å^2^) of the total BSA on the V~H~ domain ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). However, in contrast to other front layer-specific bNAbs in which the CDRH3 plays a dominant role in the interactions with E2 envelope ([@bib10]; [@bib17]; [@bib28]), the main contributor to the AR3X-E2ecto binding interface was CDRH2, which accounted for 48.2% (602 Å^2^) of the total BSA of the V~H~ domain, with the majority of the binding footprint provided by the CDRH2 insertion (45.4% or 567 Å^2^ of total BSA of the V~H~ domain) ([Figure 4C](#fig4){ref-type="fig"}).

We next investigated the frequency of antibodies with 14-residue CDRH2 insertions. While the size of an insertion or deletion in human antibody genes ranges from 3 to 33 nucleotides ([@bib14]), AR3X has a unusually long 42-nucleotide insertion, which results in a 31-residue CDRH2 (Kabat definition: \[[@bib13]\]). According to the abYsis database ([@bib26]), a typical human CDRH2 is 17 residues (relative frequency 67%) ([Figure 4D](#fig4){ref-type="fig"}), and CDRH2s longer than 20 residues are rare (relative frequency \<1%). To our knowledge, AR3X with its 31-residue CDRH2 represents the longest CDRH2 among antibody structures available in the Protein Data Bank (PDB).

Although the CDH3s of AR3X, AR3A, AR3C, HEPC3, and HEPC74 CDRH3s make similar binding footprints on the E2 surface ([Figure 5](#fig5){ref-type="fig"}), the difference in Fab approach angles and the presence of the long insertion in the AR3X CDRH2 result in different footprints on E2 for the *V~H~1-69*--encoded CDRH2 loops of the bNAbs: AR3X CDRH2 contacts the C-terminus of the E2 α1-helix, the portion of the E2 front layer between the α-helix, variable region 2 (residues 446--448), and the back layer of E2 (residues 444, 445) ([Figure 4F](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). In contrast, the AR3A and AR3C CDRH2 contacts are reduced to hydrophobic residues in α1-helix ([@bib17]), whereas the HEPC3 and HEPC74 CDRH2s contact the E2 α1-helix and the portion of the E2 front layer between the α1-helix and variable region 2 (residues 446--448) ([@bib10]).

![A structural plasticity of *VH1-69-*derived bNAbs with the CDRH3 disulfide motif.\
(Top) Surface representations of AR3X-E2 and other bNAb-E2 structures. E2, gray; AR3A-HC, red; AR3A-LC, light red; AR3C-HC, orange; AR3C-LC, yellow; AR3X-HC, green; AR3X-LC, light green; HEPC3-HC, blue; HEPC3-LC, light blue; HEPC74-HC, purple; HEPC74-LC, pink. (Bottom) Comparison of AR3A (red), AR3C (orange), AR3X (green), HEPC3 (blue), and HEPC74 (purple) epitopes. Epitopes on the E2 front layer (surface representation) were defined as residues in E2 containing an atom within 4 Å of the bound Fab.](elife-53169-fig5){#fig5}

A feature of *VH1-69*-derived antibodies is the presence of two hydrophobic residues at the tip of the CDRH2 loop that facilitate interactions with hydrophobic epitopes. The CDRH2s of AR3A and AR3C contain an Ile/Val-Pro-Met/Leu-Phe motif in which hydrophobic residues interact with the E2 front layer and CD81 binding loop ([@bib5]). The CDRH2s of HEPC3 and HEPC74 are less hydrophobic and contain a Thr/Ser-Pro-Ile-Phe/Ser motif ([@bib5]). In addition to hydrophobic interactions with the E2 front layer, the HEPC3 CDRH2 also makes a single hydrogen bond with E2 ([@bib10]). By contrast, AR3X is a not a typical *VH1-69* antibody in which hydrophobic residues in CDRH2 mediate the binding to hydrophobic residues in E2 ([@bib5]). Instead, the AR3X CDRH2 forms eight hydrogen bonds with the E2 glycoprotein, four of which are mediated by AR3X residue Arg52g (AR3X-E2ecto: Pro52c-His445, Pro52e-Thr444, Arg52g-Ala440, Arg52g-Phe442, Arg52g-Tyr443, Arg52g-Pro612, Asn52n-Tyr443, Trp52i-Tyr613) ([Figure 4F](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Notably, these differences in binding interactions have functional implications, as these mAbs differ in potency of neutralization of individual HCV strains in the HCVpp panel. For example, the AR3X neutralization IC~50~ for strain 1b21 is \~17 fold lower than the IC~50~ of HEPC3 (1.2 vs. 20.5 µg/mL). In contrast, the AR3X neutralization IC~50~ for strain 1a142 is \~9 fold higher than the IC~50~ of HEPC3 (16.2 vs. 1.9 µg/mL) ([Figure 2](#fig2){ref-type="fig"}; [@bib10]).

A signature feature of the AR3A/AR3C and HEPC3/HEPC74 types of HCV bNAbs is the long CDRH3 that forms multiple main chain--main chain hydrogen bonds with E2 front layer residues ([@bib10]; [@bib28]). Similar to other front layer-specific bNAbs with a CDRH3 disulfide motif, the first cysteine residue of the AR3X CDRH3 (Cys100a) hydrogen bonds with E2 residue Cys429 ([Figure 4G](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}; [@bib10]; [@bib17]; [@bib28]). Three additional hydrogen bonds (AR3X-E2ecto: Arg99-Asp431, Arg99-Asn430, Asn96-Asp431), as well as a salt bridge between CDRH3 (Arg100b) and a CD81 binding loop residue (Glu531), further stabilize the interaction of AR3X with E2. The AR3X-E2ecto crystal structure also shows contacts between the AR3X CDRH3 and N-glycans attached to E2 residues Asn423 and Asn430 ([Figure 4G](#fig4){ref-type="fig"}).

Discussion {#s3}
==========

We and others previously described HCV bNAbs that utilize the *VH1-69* gene segment and a germline-encoded disulfide motif in CDRH3 to recognize the conserved epitope in E2 front layer ([@bib10]; [@bib15]; [@bib17]; [@bib28]). Here we structurally characterized a front layer-specific HCV bNAb that is encoded by the *VH1-69* gene that includes an ultralong insertion in CDRH2 as well as the disulfide motif in CDRH3. We found that AR3X, isolated from the same chronically-infected patient as AR3A or AR3C ([@bib20]), surprisingly exhibits the straight CDRH3 conformation found in the HEPC3 or HEPC74 bNAbs isolated from individuals who spontaneously cleared HCV infection ([Figure 3](#fig3){ref-type="fig"}). This indicates that a single individual can produce potent HCV-specific bNAbs using the common *VH1-69* and *D2-15* genes that bind to the conserved region of E2 in at least three different configurations (straight CDRH3 with CDRH2 insertion, straight CDRH3 without CDRH2 insertion, or bent CDRH3 without CDRH2 insertion), highlighting the intrinsic plasticity of the *VH1-69*--encoded CDRH1 and CDRH2 loops that accommodate different antibody approach angles ([Figure 5](#fig5){ref-type="fig"}). It's likely that the CDRH3s of these bNAbs dictate the preferential mode of engagement of bNAb germline precursors with the conserved epitope in the E2 front layer. Overall, these data demonstrate that B cells using VH1-69 and D2-15 genes can follow multiple pathways of affinity maturation to achieve broad neutralizing activity.

In the four bNAbs that were previously characterized structurally ([@bib10]; [@bib17]; [@bib28]), the first cysteine residue of the CDRH3 hydrogen bonds with E2 residue Cys429 ([Figure 4G](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). We hypothesize that after the initial recognition of the front layer by CDRH3, the *VH1-69*-encoded CDRH1 and CDRH2 further stabilize the interaction while subsequent somatic mutations increase the bNAb affinity and breadth. Other antibodies that utilize a CDRH3 stabilized by a disulfide bond have been also described in the literature ([@bib25]; [@bib27]; [@bib31]). For example, M336, a potent human antibody that neutralizes severe acute respiratory syndrome coronavirus ([@bib30]), is encoded by the *VH1-69* gene segment and includes a germline-encoded disulfide bond in its CDRH3 ([@bib31]).

Nucleotide insertions and deletions play an important role in diversification of the antibody repertoire ([@bib6]; [@bib24]; [@bib29]). Insertions are produced by sequence duplications; while the average size of insertion varies from 3 to 33 nucleotides, the majority of antibodies contain short insertions ([@bib14]; [@bib29]). AR3X with its 42-nucleotide insertion in CDRH2 represents an interesting case of an antibody that utilizes an ultralong CDRH2 to bind its epitope ([Figure 4](#fig4){ref-type="fig"}). The insertion was required for recognition of E2 glycoproteins across multiple HCV strains, as evidenced by the poor binding activity of AR3X variants lacking the CDRH2 insertion ([Figure 2](#fig2){ref-type="fig"}). While several neutralizing antibodies with insertions have been described ([@bib16]; [@bib18]), AR3X is unique for its exceptionally long CDRH2 insertion, which makes extensive contacts with E2, but does not change the preconfigured mode of AR3X interaction with E2 based on its straight CDRH3 containing a disulfide motif. Thus the conserved epitope in the HCV E2 front layer, which is recognized by multiple human bNAbs containing a disulfide motif in their CDRH3s ([Figure 5](#fig5){ref-type="fig"}), remains a promising target for lineage-based immunogen design.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                                                        Source or reference                   Identifiers                                                    Additional\
  (species) or resource                                                                                                                                                                                information
  ---------------------------- ------------------------------------------------------------------ ------------------------------------- -------------------------------------------------------------- -----------------
  Cell line (*Homo-sapiens*)   HEK293-6E                                                          National Research Council of Canada   11565                                                          

  Cell line (*Homo-sapiens*)   Expi293F                                                           Thermo Fisher Scientific              A14527                                                         

  Cell line (*Homo-sapiens*)   Hep3B2.1--7                                                        ATCC                                  HB-8064                                                        

  Antibody                     Anti-Human IgG-HRP (Goat polyclonal)                               SouthernBiotech                       2040--05                                                       1:4000 dilution

  Recombinant DNA reagent      pTT5 mammalian expression vector (used to express IgGs and Fabs)   National Research Council of Canada   N/A                                                            

  Commercial assay or kit      1-Step Ultra TMB-ELISA Substrate Solution                          Thermo Fisher Scientific              34028                                                          

  Commercial assay or kit      PEGRx HT                                                           Hampton Research                      HR2-086                                                        

  Commercial assay or kit      PEG/Ion HT                                                         Hampton Research                      HR2-139                                                        

  Commercial assay or kit      JCSG-plus HT-96                                                    Molecular Dimensions                  MD1-40                                                         

  Chemical compound, drug      Kifunensine                                                        Sigma                                 K1140                                                          

  Software, algorithm          Pymol                                                              Schrödinger, LLC                      RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)   

  Software, algorithm          Phenix                                                             ([@bib1])                             <https://www.phenix-online.org>                                

  Software, algorithm          Coot                                                               ([@bib8])                             <http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>         

  Software, algorithm          PDBePISA                                                           ([@bib19])                            <http://www.ebi.ac.uk/pdbe/pisa/>                              

  Software, algorithm          abYsis system                                                                                            <http://www.bioinf.org.uk/abysis/>                             

  Other                        Superdex 200 Increase 10/300 GL                                    GE Healthcare                         17517501                                                       

  Other                        HisTrap FF column                                                  GE Healthcare                         17531901                                                       

  Other                        HiTrap Protein A HP column                                         GE Healthcare                         17040301                                                       

  Other                        HCV 1b09 strain E1E2 sequence                                      GenBank                               KJ187984.1                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines {#s4-1}
----------

HEK293-6E cells were obtained from National Research Council of Canada. Expi293F cells were obtained from Thermo Fisher Scientific. Hep3B cells were obtained from American Type Culture Collection (ATCC). Hep3B cells were tested for mycoplasma contamination. Neither cell line is among the list of commonly misidentified cell lines.

IgG expression and purification {#s4-2}
-------------------------------

Genes encoding the V~H~ and V~L~ domains of the AR3X bNAb called antibody 'A' in Supplemental Table 1 in [@bib20] were synthesized as gBlocks gene fragments (IDT) and cloned into pTT5-based expression vectors (NRC Biotechnology Research Institute). Reverted unmutated ancestor (rua) variants of AR3X and the location of the insertion were inferred with IMGT/V-QUEST using complete sequences of heavy and light chain variable domains. IgGs were produced in Expi293F cells (National Research Council of Canada) by co-transfecting appropriate heavy and light chain plasmids. HiTrap Protein A HP column (GE Healthcare) was used to isolate IgGs from filtered culture supernatants followed by purification by size exclusion chromatography (SEC) using a Superdex 200 Increase 10/300 GL column (GE Healthcare).

Expression and purification of E2 constructs {#s4-3}
--------------------------------------------

For ELISA experiments, His-tagged E2ecto proteins (residues 384--643) were expressed by transiently transfecting Expi293F cells (National Research Council of Canada) and purified from clarified supernatants using a HisTrap FF column (GE Healthcare) followed by SEC on a Superdex 200 Increase 10/300 GL column (GE Healthcare) to separate monomeric E2ecto proteins from oligomeric species. For structural studies, the His-tag was removed from an expression vector encoding a strain 1b09 E2 ectodomain.

Expression and purification of an E2-Fab complex {#s4-4}
------------------------------------------------

AR3X Fab-1b09 E2ecto complexes for structural studies were produced in HEK293-6E or Expi293F cells (National Research Council of Canada) in the presence of 5 μM kifunensine (Sigma) by co-transfecting expression vectors encoding His-tagged Fab and untagged E2ecto to allow isolation of stable Fab-E2 complexes ([@bib10]). AR3X-E2 complex was purified from supernatants using Ni-NTA chromatography on HisTrap HP column (GE Healthcare) followed by SEC on a Superdex 200 Increase 10/300 GL column (GE Healthcare).

Crystallization, data collection and structure determinations {#s4-5}
-------------------------------------------------------------

Commercially-available screens (Hampton Research and Molecular Dimensions) were used to screen initial crystallization conditions by vapor diffusion in sitting drops. AR2X-E2ecto crystals were grown using 0.2 µL of protein complex in TBS and 0.2 µL of mother liquor (0.25 M ammonium tartrate dibasic pH 7.0, 20% PEG 3,350) and cryoprotected in mother liquor supplemented with 20% (w/v) glycerol. X-ray diffraction data from cryopreserved crystals were collected at the Stanford Synchrotron Radiation Lightsource on beamline 12--2 using a PILATUS 6M detector. Images were processed and scaled using iMosflm ([@bib3]) and Aimless as implemented in the CCP4 software suite ([@bib9]). The AR3X-E2 complex structure was solved by molecular replacement using the AR3C (PDB 4MWF) and 1b09 HCV E2ecto (PDB 6MEI) structures as search models. The models were refined and validated using Phenix.refine ([@bib1]). Iterative manual model building and corrections were performed using Coot ([@bib8]). Glycans were initially interpreted and modeled using F~o~ -- F~c~ maps calculated with model phases contoured at 2σ, followed by 2F~o~ -- F~c~ simulated annealing composite omit maps generated in Phenix in which modeled glycans were omitted to remove model bias ([@bib1]). The quality of the final models was examined using MolProbity ([@bib4]).

Models were superimposed and figures rendered using the PyMOL molecular visualization system (Version 1.7, Schrödinger, LLC). Buried surface areas (BSAs) were determined using the PDBePISA web-based interactive tool ([@bib19]). Potential hydrogen bonds were assigned using criteria of a distance of \<4.0 Å and an A-D-H angle of \>90°, and the maximum distance allowed for a van der Waals interaction was 4.0 Å. Rmsd calculations were done in PyMOL following pairwise Cα alignments without excluding outliers. AR3X residues were numbered according to the Kabat numbering scheme, and Kabat definitions of CDRs were used throughout the paper ([@bib13]). Values to show the length distribution of CDRH2 in humans were extracted from the online abYsis system (<http://www.bioinf.org.uk/abysis/>) using the Kabat numbering scheme.

ELISA binding analyses {#s4-6}
----------------------

Soluble forms of full-length E2 ectodomains were coated overnight onto 96-well plates (Corning) at 1 μg/mL. Plates were blocked with 1% goat serum and 1% powdered milk in TBST buffer (TBS with 0.05% Tween-20) for 1 hr. Purified IgGs were assayed in duplicate at 4-fold serial dilutions, starting at 10 µg/mL. IgGs-E2ecto complexes were detected using goat anti-human IgG horseradish peroxidase-conjugated secondary antibody (Southern Biotech, 1:4000 dilution) and 1-Step Ultra TMB-ELISA substrate (Thermo Fisher Scientific) and reading the optical density read at 450 nm after stopping the reaction with 1M HCl. A non-linear regression analysis was performed on the resulting curves using Prism version 5 (GraphPad) to calculate EC~50~ values.

HCVpp production and neutralization assays {#s4-7}
------------------------------------------

HCVpp were produced by lipofectamine-mediated transfection of HCV E1E2 and pNL4-3.Luc.R-E- plasmids into HEK293T cells as described ([@bib12]; [@bib21]). A panel of 19 heterologous genotype 1 HCVpp has been described previously ([@bib2]; [@bib23]). Neutralization assays were performed as described ([@bib7]). Briefly, IgGs were serially diluted five-fold, starting at a concentration at 100 µg/ml and incubated with HCVpp for one hour prior to addition to Hep3B hepatoma cells. Luciferase activity was measured after three days and compared to that of HCVpp in media alone.
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Reviewer

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and PÃ¤ivi Ojala as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Tongqing Zhou (Reviewer \#1); Michael Houghton (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This work reported the structural and biochemical characterization of a neutralizing antibody AR3X isolated from a chronically HCV-infected individual. AR3X utilizes both its ultralong CDRH2 and a disulfide motif-containing straight CDRH3 to recognize the E2 front layer. Previous studies shown the structures of E2 complexes with front layer-specific bNAbs isolated from HCV-infected individuals, revealed a disulfide bond-containing CDRH3 that adopts straight (individuals who clear infection) or bent (individuals with chronic infection) conformation. The authors thus concluded that both the straight and bent CDRH3 classes of HCV bNAb can be elicited in a single individual, revealing a structural plasticity of VH1-69-derived bNAbs. This study is interesting and important for the readers interested in HCV vaccine development. There are some comments from the reviewers to be addressed, but no more experiments are needed.

Reviewer \#1:

The manuscript by Andrew Flaky and colleagues titled \"An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein\" reported the structural and biochemical characterization of a neutralizing antibody AR3X isolated from a chronically HCV-infected individual, the crystal structure of antibody AR3X in complex with HCV E2 glycoprotein reveals some unusual features of antibody recognition of a conserved epitope on the E2 protein. Comparison with structures of other HCV E2-targeting antibodies showed distinct antibody binding poses. It has been observed that the disulfide bond-containing CDRH3 of HCV E2 front layer-targeting antibodies adopt a \"straight\" conformation while CDR H3 of antibodies isolated from chronically infected patients adopts a bent conformation. Structural analysis of AR3X, however, revealed its CDR H3 assumes a straight conformation, which indicates that both the straight and bent CDRH3 classes of HCV bNAb can be elicited in a single individual.

The paper is clearly written and presented an interesting structural phenomenon. However, it is not clear how these special new features relate to its biological function.

Specifically, I have some comments/questions:

1\) Was AR3X broader in neutralization than others such as AR3A and AR3C?

2\) Did the new structure features, such as long CDR H2 and straightened CDR H3, contribute to its breadth?

3\) How does the epitope of AR3X look like on HCV E2? How does it compare to others\'?

4\) Is the footprint of AR3X bigger than the other ones? Does this make it harder for virus to escape?

5\) The authors mentioned the different mode of recognition, a direct comparison of antibody mode of recognition by different antibodies on superposed on E2 will be much appreciated.

6\) It will be helpful to readers if the authors show alignment of CDR H3 for AR3X and others. Is there a sequence feature that caused the \"bent\"?

7\) Does the long CDR H2 affect the conformation of CDR H3 and make it straight?

Reviewer \#2:

This very nice piece of work demonstrates that different HCV neutralising antibodies targeting the same conserved epitope isolated from the same patient bind in 3 different modes. The latter are due to the observed plasticity of the VH1-69 encoded CDRH1 and CDRH2 loops that facilitate different angles of antibody binding. This is important not just in demonstrating how neutralising antibodies mature in diverse ways in the same individual, but also in the context of using this information to design immunogens that could cross-neutralise a broader range of diverse HCVs. This approach could lead to an improved vaccine since the diverse antibodies have very different cross-neutralisation profiles.

Reviewer \#3:

Flyak et al. analyzed the novel HCV E2 antibody, AR3X isolated from chronic carrier. AR3X utilizes both its ultralong CDRH2 and a disulfide motif-containing straight CDRH3 to recognize the E2 front layer. Previous studies shown the structures of E2 complexes with front layer-specific bNAbs isolated from HCV-infected individuals, revealed a disulfide bond-containing CDRH3 that adopts straight (individuals who clear infection) or bent (individuals with chronic infection) conformation. The authors thus concluded that both the straight and bent CDRH3 classes of HCV bNAb can be elicited in a single individual, revealing a structural plasticity of VH1-69-derived bNAbs. This study is interesting and important for the readers interested in HCV vaccine development. It is important to know the maturation process of B-cell which produce broadly neutralizing antibodies. The authors found the importance of both the CDRH2 insertion and the somatic mutations on AR3X binding and neutralization. Please clarify this unusual insertion is prerequisite for the somatic mutations or vice versa.

1\) Figure 1D, indicated sequences of CDRH1, CDRH2, CDRH3 are different from their previous paper, Flyak et al., 2018. Please clarify the differences.

2\) Figure 1C, there is no description about J3\*02 in the text and legend.

3\) Figure 2, it is interesting to know the effects of 17 somatic mutation and 14aa insertion for the biding and neutralization activities on other genotypes of E2 proteins.
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Author response

> Reviewer \#1: The paper is clearly written and presented an interesting structural phenomenon. However, it is not clear how these special new features relate to its biological function.Specifically, I have some comments/questions:1) Was AR3X broader in neutralization than others such as AR3A and AR3C?

We thank the reviewer for the question. We added the following sentence to the main text: \"The neutralization breadth of AR3X (89%) was slightly lower than the breath of AR3C bNAb (100%) (Flyak et al., 2018), which was isolated from the same HCV-infected individual (Law et al., 2008).\"

> 2\) Did the new structure features, such as long CDR H2 and straightened CDR H3, contribute to its breadth?

We edited the main text of manuscript to clarify the contribution of CDRH2 to the neutralization breadth of AR3X: \"AR3X variants failed to neutralize HCV isolates, suggesting that both the CDRH2 insertion and somatic mutations are required for the *broad* neutralization activity of AR3X.\" Regarding the conformation of CDRH3 (straight or bent), we believe that the CDRH3 conformation does not directly translates into reduced or increased neutralization potency of an HCV-specific bNAb. Instead, the conformation of CDRH3 dictates the preferred mode of engagement of bNAb germline precursors with the conserved epitope in the E2 front layer, while subsequent somatic mutations and CDRH2 insertion further modulate the AR3X neutralization breadth.

> 3\) How does the epitope of AR3X look like on HCV E2? How does it compare to others\'?

The epitope of AR3X is similar to epitopes of other VH1-69 derived bNAbs with a CDRH3 disulfide motif. We added an additional figure to the manuscript (new Figure 5), which provides comparison of the AR3A, AR3C, AR3X, HEPC3, and HEPC74 epitopes.

> 4\) Is the footprint of AR3X bigger than the other ones? Does this make it harder for virus to escape?

Overall, AR3X has a similar binding footprint to the footprints of HEPC3, HEPC74, AR3C, and AR3A, sharing multiple contact residues in the front layer and CD81 receptor-binding loop. We included this information in the main text (Results, fifth paragraph). In terms of the ability of HCV to escape from front layer-specific bNAbs, we believe that the amino acid variability within the epitope might impact the ability of the virus to escape neutralization by an antibody. For example, antibodies with smaller binding footprints that bind to the conserved region might display broader neutralizing activity than antibodies that make additional contacts through less conserved regions of E2 glycoprotein.

> 5\) The authors mentioned the different mode of recognition, a direct comparison of antibody mode of recognition by different antibodies on superposed on E2 will be much appreciated.

We thank the reviewer for the suggestion. We now included the comparison of different bNAbE2 binding orientations in the new Figure 5, which also displays AR3X and other bNAb epitopes.

> 6\) It will be helpful to readers if the authors show alignment of CDR H3 for AR3X and others. Is there a sequence feature that caused the \"bent\"?

We now included the CDRH3 alignment for AR3X and other bNAbs in Figure 1E. Both the position of disulfide motif relative to the whole CDRH3 as well as the presence of specific amino acids before or after the disulfide motif might be responsible for the straight/bent conformation of CDRH3. Further mutagenesis and structural studies are needed to determine the sequence motif responsible for distinct CDRH3 conformations.

> 7\) Does the long CDR H2 affect the conformation of CDR H3 and make it straight?

We now included the CDRH3 alignment for AR3X and other bNAbs in Figure 1E. Both the position of disulfide motif relative to the whole CDRH3 as well as the presence of specific amino acids before or after the disulfide motif might be responsible for the straight/bent conformation of CDRH3. Further mutagenesis and structural studies are needed to determine the sequence motif responsible for distinct CDRH3 conformations.

> Reviewer \#3: Flyak, et al. analyzed the novel HCV E2 antibody, AR3X isolated from chronic carrier. AR3X utilizes both its ultralong CDRH2 and a disulfide motif-containing straight CDRH3 to recognize the E2 front layer. Previous studies shown the structures of E2 complexes with front layer-specific bNAbs isolated from HCV-infected individuals, revealed a disulfide bond-containing CDRH3 that adopts straight (individuals who clear infection) or bent (individuals with chronic infection) conformation. The authors thus concluded that both the straight and bent CDRH3 classes of HCV bNAb can be elicited in a single individual, revealing a structural plasticity of VH1-69-derived bNAbs. This study is interesting and important for the readers interested in HCV vaccine development. It is important to know the maturation process of B-cell which produce broadly neutralizing antibodies. The authors found the importance of both the CDRH2 insertion and the somatic mutations on AR3X binding and neutralization. Please clarify this unusual insertion is prerequisite for the somatic mutations or vice versa.

We agree with the reviewer that it is an interesting point. However, since the insertions are introduced during somatic hypermutation, it is challenging to determine whether the ultra-long insertion in CDRH2 of AR3X happens before, after, or at the same time as other somatic mutations are introduced. AR3X, along with AR3A and AR3C, was isolated from an individual who was chronically infected with HCV. By sequencing the antibody repertoire of this individual, one can potentially determine the architecture of AR3X lineage from which we could then infer events leading to the development of mature AR3X. Unfortunately, we do not have access to human samples that would enable such experiments, and such studies are outside the scope of this manuscript.

> 1\) Figure 1D, indicated sequences of CDRH1, CDRH2, CDRH3 are different from their previous paper, Flyak et al., 2018. Please clarify the differences.

The observed differences are due to the different systems used to define CDR loops between two manuscripts. In our previous paper (Flyak et al., 2018), CDR loops were defined based on IMGT nomenclature. In the current manuscript, Kabat definitions of CDRs were used throughout the paper to allow a direct comparison of the AR3X structure with the recently-published structure of AR3A (Tzarum et al., 2019). The use of the Kabat numbering scheme is mentioned in the Materials and methods and in the legend to Figure 1.

> 2\) Figure 1C, there is no description about J3\*02 in the text and legend.

We added the description of J3\*02 to the main text (Results, first paragraph).

> 3\) Figure 2, it is interesting to know the effects of 17 somatic mutation and 14aa insertion for the biding and neutralization activities on other genotypes of E2 proteins.

This is an excellent suggestion. We have now evaluated the binding of AR3X and AR3X variants to a panel of E2 proteins representing six HCV genotypes (see updated Figure 2A and Figure 2---figure supplement 1). We also updated the main text to discuss the new results (Results, second paragraph). In summary, only mature AR3X recognized E2 glycoproteins from genotypes 2-6. AR3X DINS, AR3Xrua + INS, and AR3Xrua did not bind to E2 proteins from genotypes 2-6. These results further support our hypothesis that immunogens based on the genotype 1 1a157 ectodomain sequence could be used to stimulate the development of potent front layer-specific bNAbs.
